Article Type
Changed
Fri, 12/16/2022 - 12:38
Display Headline
FDA approves lenalidomide for mantle cell lymphoma

The Food and Drug Administration has approved lenalidomide for the treatment of patients whose mantle cell lymphoma has relapsed or progressed after two prior therapies, one of which included bortezomib.

Lenalidomide, a thalidomide analogue, is already approved for use in combination with dexamethasone for multiple myeloma in patients who have received at least one prior therapy. Lenalidomide also is approved for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.

"There remains a tremendous unmet need for [therapies for] patients with previously treated mantle cell lymphoma," said Dr. Andre Goy, chairman and director, and chief of the division of lymphoma at the John Theurer Cancer Center at Hackensack (N.J.) University Medical Center, in a statement issued by lenalidomide maker Celgene. "The approval of lenalidomide delivers a new option and the first oral therapy in this area of lymphoma."

Mantle cell lymphoma is fairly rare, accounting for about 6% of the 66,360 new cases of non-Hodgkin’s lymphoma diagnosed in the United States each year, according to the Leukemia and Lymphoma Society.

The Food and Drug Administration (FDA) said it based its approval on a single-arm, multicenter study with 134 patients who had relapsed after or were refractory to bortezomib or a bortezomib-containing regimen. In the 133 patients who were evaluable for efficacy, the overall lenalidomide response rate was 26%. Nine patients (7%) had a complete response or unconfirmed complete response, and 25 (19%) had a partial response. In the 34 responders, the median duration of response was 16.6 months.

Due to adverse events, a little more than half of the patients had to interrupt therapy; 38% had a dose reduction and 19% discontinued therapy. The most common reactions included neutropenia, thrombocytopenia, fatigue, anemia, diarrhea, nausea, cough, pyrexia, rash, dyspnea, pruritus, constipation, peripheral edema, and leukopenia, according to the FDA.

In May 2012, the agency also determined that patients taking the drug for newly diagnosed multiple myeloma are at increased risk for secondary cancers.

Lenalidomide was approved at a recommended dose and schedule of 25 mg orally once daily on days 1-21 of repeated 28-day cycles. Celgene also received approval for a new 20-mg strength of lenalidomide.

aault@frontlinemedcom.com

On Twitter @aliciaault

Author and Disclosure Information

Publications
Topics
Legacy Keywords
FDA, Food and Drug Administration, lenalidomide, mantle cell lymphoma, bortezomib, transfusion-dependent anemia
Author and Disclosure Information

Author and Disclosure Information

Related Articles

The Food and Drug Administration has approved lenalidomide for the treatment of patients whose mantle cell lymphoma has relapsed or progressed after two prior therapies, one of which included bortezomib.

Lenalidomide, a thalidomide analogue, is already approved for use in combination with dexamethasone for multiple myeloma in patients who have received at least one prior therapy. Lenalidomide also is approved for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.

"There remains a tremendous unmet need for [therapies for] patients with previously treated mantle cell lymphoma," said Dr. Andre Goy, chairman and director, and chief of the division of lymphoma at the John Theurer Cancer Center at Hackensack (N.J.) University Medical Center, in a statement issued by lenalidomide maker Celgene. "The approval of lenalidomide delivers a new option and the first oral therapy in this area of lymphoma."

Mantle cell lymphoma is fairly rare, accounting for about 6% of the 66,360 new cases of non-Hodgkin’s lymphoma diagnosed in the United States each year, according to the Leukemia and Lymphoma Society.

The Food and Drug Administration (FDA) said it based its approval on a single-arm, multicenter study with 134 patients who had relapsed after or were refractory to bortezomib or a bortezomib-containing regimen. In the 133 patients who were evaluable for efficacy, the overall lenalidomide response rate was 26%. Nine patients (7%) had a complete response or unconfirmed complete response, and 25 (19%) had a partial response. In the 34 responders, the median duration of response was 16.6 months.

Due to adverse events, a little more than half of the patients had to interrupt therapy; 38% had a dose reduction and 19% discontinued therapy. The most common reactions included neutropenia, thrombocytopenia, fatigue, anemia, diarrhea, nausea, cough, pyrexia, rash, dyspnea, pruritus, constipation, peripheral edema, and leukopenia, according to the FDA.

In May 2012, the agency also determined that patients taking the drug for newly diagnosed multiple myeloma are at increased risk for secondary cancers.

Lenalidomide was approved at a recommended dose and schedule of 25 mg orally once daily on days 1-21 of repeated 28-day cycles. Celgene also received approval for a new 20-mg strength of lenalidomide.

aault@frontlinemedcom.com

On Twitter @aliciaault

The Food and Drug Administration has approved lenalidomide for the treatment of patients whose mantle cell lymphoma has relapsed or progressed after two prior therapies, one of which included bortezomib.

Lenalidomide, a thalidomide analogue, is already approved for use in combination with dexamethasone for multiple myeloma in patients who have received at least one prior therapy. Lenalidomide also is approved for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.

"There remains a tremendous unmet need for [therapies for] patients with previously treated mantle cell lymphoma," said Dr. Andre Goy, chairman and director, and chief of the division of lymphoma at the John Theurer Cancer Center at Hackensack (N.J.) University Medical Center, in a statement issued by lenalidomide maker Celgene. "The approval of lenalidomide delivers a new option and the first oral therapy in this area of lymphoma."

Mantle cell lymphoma is fairly rare, accounting for about 6% of the 66,360 new cases of non-Hodgkin’s lymphoma diagnosed in the United States each year, according to the Leukemia and Lymphoma Society.

The Food and Drug Administration (FDA) said it based its approval on a single-arm, multicenter study with 134 patients who had relapsed after or were refractory to bortezomib or a bortezomib-containing regimen. In the 133 patients who were evaluable for efficacy, the overall lenalidomide response rate was 26%. Nine patients (7%) had a complete response or unconfirmed complete response, and 25 (19%) had a partial response. In the 34 responders, the median duration of response was 16.6 months.

Due to adverse events, a little more than half of the patients had to interrupt therapy; 38% had a dose reduction and 19% discontinued therapy. The most common reactions included neutropenia, thrombocytopenia, fatigue, anemia, diarrhea, nausea, cough, pyrexia, rash, dyspnea, pruritus, constipation, peripheral edema, and leukopenia, according to the FDA.

In May 2012, the agency also determined that patients taking the drug for newly diagnosed multiple myeloma are at increased risk for secondary cancers.

Lenalidomide was approved at a recommended dose and schedule of 25 mg orally once daily on days 1-21 of repeated 28-day cycles. Celgene also received approval for a new 20-mg strength of lenalidomide.

aault@frontlinemedcom.com

On Twitter @aliciaault

Publications
Publications
Topics
Article Type
Display Headline
FDA approves lenalidomide for mantle cell lymphoma
Display Headline
FDA approves lenalidomide for mantle cell lymphoma
Legacy Keywords
FDA, Food and Drug Administration, lenalidomide, mantle cell lymphoma, bortezomib, transfusion-dependent anemia
Legacy Keywords
FDA, Food and Drug Administration, lenalidomide, mantle cell lymphoma, bortezomib, transfusion-dependent anemia
Article Source

PURLs Copyright

Inside the Article